Clinical Trial · NCT07590336

68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma

Overview

This is a prospective, single-center, single-arm, phase I/II study designed to evaluate (1) the safety, tolerability, and imaging characteristics of 68Ga-NYM207 (Phase A), and (2) the diagnostic performance of 68Ga-NYM207 in detecting hepatocellular carcinoma (HCC) (Phase B). This study will provide critical insights into the performance of 68Ga-NYM207 PET/CT as a non-invasive imaging tool for the detection of HCC.

Sponsor

Peking Union Medical College Hospital

Phase

Phase 1/2

Contacts

Li Huo (CONTACT)

huoli@pumch.cn

+86 18612672038

Wenjia Zhu (CONTACT)

zhuwenjia_pumc@163.com

+86 18614080164

ClinicalTrials.gov

NCT07590336

Eligibility

Inclusion

with a history of HCC, recurrence or metastasis during follow-up (based on histopathologic examination or typical appearance of imaging data including conventional imaging or 18F-FDG PET/CT scan);
Written informed consent provided for participation in the trial;
1. ≥18 years of age and of either gender;
At least one of the following indications should be applied:
scheduled for surgical resection or biopsy of the liver mass within one month;

Exclusion

Any condition deemed by the investigator to interfere with study results or increase participant risk.
Severe claustrophobia;
1. Pregnancy or lactation;
On treatment with anti-tumor drugs targeting GPC3;